An herbal-based intravenous product significantly lowered the risk of death in sepsis patients with moderate to severe illness, according to results of a large randomized trial conducted in China.
At 28 days, 18.8% of patients who received 5 days of Xuebijing injections died versus 26.1% in a placebo group, for a risk difference of 7.3 percentage points (95% CI 3.4-11.2, P